AbCellera Biologics Inc. (ABCL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABCL POWR Grades
- Value is the dimension where ABCL ranks best; there it ranks ahead of 86.36% of US stocks.
- ABCL's strongest trending metric is Sentiment; it's been moving down over the last 178 days.
- ABCL ranks lowest in Momentum; there it ranks in the 4th percentile.
ABCL Stock Summary
- ABCL's went public 1.96 years ago, making it older than merely 9.09% of listed US stocks we're tracking.
- Of note is the ratio of ABCELLERA BIOLOGICS INC's sales and general administrative expense to its total operating expenses; only 10.6% of US stocks have a lower such ratio.
- With a year-over-year growth in debt of 162.58%, ABCELLERA BIOLOGICS INC's debt growth rate surpasses 91.47% of about US stocks.
- If you're looking for stocks that are quantitatively similar to ABCELLERA BIOLOGICS INC, a group of peers worth examining would be ASTR, VRCA, AMWL, CORT, and VRAR.
- To dig deeper into the stock's financial statements, go to ABCL's page on browse-edgar?action=getcompany&CIK=0001703057.
ABCL Valuation Summary
- In comparison to the median Healthcare stock, ABCL's price/sales ratio is 33.33% higher, now standing at 6.4.
- Over the past 24 months, ABCL's price/sales ratio has gone down 1342.6.
Below are key valuation metrics over time for ABCL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ABCL | 2022-11-25 | 6.4 | 3.1 | 15.6 | 9.8 |
| ABCL | 2022-11-23 | 6.6 | 3.2 | 16.1 | 10.2 |
| ABCL | 2022-11-22 | 6.6 | 3.2 | 16.1 | 10.2 |
| ABCL | 2022-11-21 | 6.7 | 3.2 | 16.2 | 10.3 |
| ABCL | 2022-11-18 | 6.7 | 3.2 | 16.3 | 10.3 |
| ABCL | 2022-11-17 | 6.7 | 3.2 | 16.2 | 10.3 |
ABCL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ABCL has a Quality Grade of C, ranking ahead of 74.92% of graded US stocks.
- ABCL's asset turnover comes in at 0.453 -- ranking 98th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ABCL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0.453 | 1 | 1.811 |
ABCL Price Target
For more insight on analysts targets of ABCL, see our ABCL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $45.40 | Average Broker Recommendation | 1.3 (Strong Buy) |
ABCL Stock Price Chart Interactive Chart >
ABCL Price/Volume Stats
| Current price | $13.56 | 52-week high | $15.90 |
| Prev. close | $13.52 | 52-week low | $5.42 |
| Day low | $13.36 | Volume | 1,245,500 |
| Day high | $13.73 | Avg. volume | 2,107,648 |
| 50-day MA | $11.51 | Dividend yield | N/A |
| 200-day MA | $10.05 | Market Cap | 3.88B |
AbCellera Biologics Inc. (ABCL) Company Bio
AbCellera focuses on therapeutic antibodies, screening, choosing, and analyzing millions of naturally produced antibodies to be used as next-generation drug candidates. It specializes in the fields of biotechnology, medicine, and therapeutics. It was founded in 2012 and headquartered in Vancouver, British Columbia.
Latest ABCL News From Around the Web
Below are the latest news stories about ABCELLERA BIOLOGICS INC that investors may wish to consider to help them evaluate ABCL as an investment opportunity.
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022VANCOUVER, British Columbia, November 10, 2022--AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022 |
Analysts Offer Insights on Healthcare Companies: Bayer (OtherBAYRY), Mirati Therapeutics (MRTX) and AbCellera Biologics (ABCL)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bayer (BAYRY – Research Report), Mirati Therapeutics (MRTX – Research Report) and AbCellera Biologics (ABCL – Research Report). Bayer (BAYRY) In a report released today, Joel Jackson from BMO Capital maintained a Hold rating on Bayer, with a price target of EUR66.00. The company's shares closed last Wednesday at $12.60. According to TipRanks.com, Jackson is a 5-star analyst with an average return of -9.1% and a 40.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Bausch Health Companies, Aquestive Therapeutics, and Pacira Pharmaceuticals. |
Analysts’ Top Healthcare Picks: Mirati Therapeutics (MRTX), AbCellera Biologics (ABCL)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mirati Therapeutics (MRTX – Research Report), AbCellera Biologics (ABCL – Research Report) and Beauty Health (SKIN – Research Report) with bullish sentiments. Mirati Therapeutics (MRTX) SVB Securities analyst Andrew Berens maintained a Buy rating on Mirati Therapeutics today and set a price target of $102.00. The company's shares closed last Tuesday at $59.44. According to TipRanks.com, Berens is a 4-star analyst with an average return of -12.0% and a 36.1% success rate. Souda covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Twist Bioscience, and Myriad Genetics. |
AbCellera Biologics Inc. (ABCL) Q3 2022 Earnings Call TranscriptImage source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL)Q3 2022 Earnings CallNov 08, 2022, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, and welcome to AbCellera's third quarter 2022 business update conference call. |
AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss EstimatesAbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
ABCL Price Returns
| 1-mo | 15.80% |
| 3-mo | 26.97% |
| 6-mo | 75.65% |
| 1-year | -3.83% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -5.17% |
| 2021 | -64.46% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...